Reset filter
Trefwoorden
Ovary Neoplasms ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

136 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Cancer NCT00756847

- 10-11-17 - 1 Formulier, 2 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00756847

Quality Assurance Checklist For Potential Genetic Liability By Breast Cancer and Ovarian Cancer - Checklist

- 26-06-16 - 1 Formulier, 4 Itemgroepen, 79 Data-elementen, 1 Taal
Itemgroepen: Patient information, Hereditary factor Siblings children, Hereditary factor Maternal Relative, Hereditary factor Paternal Relative
Documentation form for quality assurance in German Health Care by the Aerztekammer Wesfalen-Lippe, http://www.aekwl.de/index.php?id=1788, Form version 30. März 2016 (C)

Eligibility Ovarian Cancer NCT01180504

- 12-09-18 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01180504 Sponsor: University Hospital Heidelberg Collaborator: Deutsche Krebshilfe e.V., Bonn (Germany) Information provided by: University Hospital Heidelberg Principal Investigator: Andreas Schneeweiss, MD Department of Gyneacology and Obstetrics, Unversity of Heidelberg Principal Investigator: Juergen Debus, MD, PhD Department of Radiation Oncology, University of Heidelberg

Eligibility Ovarian Cancer NCT00721162

- 14-08-18 - 1 Formulier, 2 Itemgroepen, 34 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Ramucirumab in Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00721162

Eligibility Ovarian Cancer NCT00132522

- 29-05-17 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide; ODM derived from: https://clinicaltrials.gov/show/NCT00132522

Eligibility Ovarian Cancer NCT00181688

- 17-11-16 - 1 Formulier, 2 Itemgroepen, 21 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00181688

Oral GW786034 treatment for ovarian cancer NCT00281632 - Screening Eligibility Criteria

- 20-09-21 - 1 Formulier, 3 Itemgroepen, 31 Data-elementen, 1 Taal
Itemgroepen: Header, Inclusion Criteria, Exclusion Criteria
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Screening

- 15-03-21 - 1 Formulier, 24 Itemgroepen, 129 Data-elementen, 2 Talen
Itemgroepen: Header, Eligibility Question, Demography, Physical examination, Disease Characteristics, Metastatic Disease Site, local laboratory, Residual toxicities related to previous therapy for cancer, Residual toxicities, Cancer related current medical conditions, Medical Conditions, non-cancer related medical conditions, Medical Conditions, Prior anti-cancer therapy, Prior anti-cancer therapy - medication, Prior anti-cancer therapy - radiotherapy, Vital signs, ECOG Performance Status Scale, 12 LEAD ECG, 12-lead ECG Abnormalities, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, Electronically transferred laboratory data
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Additional Forms

- 03-06-18 - 1 Formulier, 24 Itemgroepen, 95 Data-elementen, 1 Taal
Itemgroepen: Header, investigational product discontinuation, PGx-Pharmacogenetic Research, Concomitant Medications, If Yes to Concominant Medication, Non-serious adverse events, Non-serious adverse events, Serious adverse event, Serious adverse events description, Seriousness, Document section Demography data, SECTION 4, Section 5, Relevant Medical Conditions, Document section Risk factors, Document section Concomitant Medications, Drug Details, Assessments, Document section, Pregnancy information, Death, Study Conclusion, Investigator comment log, Investigators Signature
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Unscheduled Visit

- 30-05-18 - 1 Formulier, 7 Itemgroepen, 50 Data-elementen, 1 Taal
Itemgroepen: Header, Vital signs, Electronically transferred laboratory data, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, 12 LEAD ECG
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Post-Treatment Assessments

- 16-05-18 - 1 Formulier, 12 Itemgroepen, 54 Data-elementen, 1 Taal
Itemgroepen: Header, Vital signs, ECOG Performance Status Scale, Electronically transferred laboratory data, Physical examination, serum pregnancy test, CONCOMITANT MEDICATIONS, ADVERSE EVENTS, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, 12 LEAD ECG
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Visit description: Treatment Period 3. Day 1

- 15-05-18 - 1 Formulier, 15 Itemgroepen, 64 Data-elementen, 1 Taal
Itemgroepen: Header, Vital signs, ECOG Performance Status, Electronically transferred lab data - CA-125, Physical examination, Concomitant Medication, Adverse Events, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, Pharmacokinetics Blood, Investigational Product, Biomarker sample(s), investigational product, Treatment Confirmation
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial